Real-world evidence of measurable residual disease assessment in multiple myeloma
Maria Teresa Cedena1, Noemi Puig2, Bruno Paiva3
1Hospital Universitario 12 de Octubre, Madrid, Spain.
Blood Advances
|December 11, 2025
Abstract
No abstract available in PubMed .
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.0K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
7.2K
